CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells.
CTPS1
Colorectal cancer (CRC)
biomarker
cell cycle
p53
Journal
Cell cycle (Georgetown, Tex.)
ISSN: 1551-4005
Titre abrégé: Cell Cycle
Pays: United States
ID NLM: 101137841
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
2
8
2022
medline:
29
11
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is now the third most prevalent tumor and one of the deadliest cancers worldwide, with an increasing prevalence every year. Therefore, we urgently need to understand the mechanisms regulating the progression of colorectal cancer and find potential diagnostic biomarkers. In this study, we performed an analysis using the TCGA and GEO databases to find a molecular biomarker for the diagnosis of CRC, namely CTPS1. The results of this analysis revealed that CTPS1 could promote tumor proliferation and metastasis. Furthermore, bioinformatics analysis revealed that CTPS1 promoted CRC progression through cell cycle and p53 pathways. Further investigation demonstrated that CTPS1 might be involved in the regulation of CCNB1, RRM2, GTSE1, CDK2 and CHEK2 genes. Moreover, PCR confirmed that CTPS1 regulated GTSE1 and CDK2 molecules. Then, western blot was used to verify that CTPS1 promoted the expression of GTSE1 and CDK2 by inhibiting the expression of p53. In summary, we identified an important diagnostic biomarker for CRC, namely CTPS1, and its importance was validated at the cellular level. These results suggest that CTPS1 could serve as a candidate biomarker for CRC and CTPS1 inhibitors may be a potential treatment for CRC.
Identifiants
pubmed: 35912542
doi: 10.1080/15384101.2022.2105084
pmc: PMC9704378
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
GTSE1 protein, human
0
Microtubule-Associated Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2563-2574Références
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
EMBO Mol Med. 2018 Feb;10(2):188-199
pubmed: 29282224
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Oncotarget. 2016 Dec 13;7(50):83187-83199
pubmed: 27825122
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jul 1;62(Pt 7):613-7
pubmed: 16820675
Cytokine Growth Factor Rev. 2016 Oct;31:73-81
pubmed: 27502919
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32161190
J Biol Chem. 1998 Jul 24;273(30):18992-9001
pubmed: 9668079
JAMA. 2016 Jun 21;315(23):2576-94
pubmed: 27305422
J Transl Med. 2022 Jan 6;20(1):17
pubmed: 34991621
Ann Transl Med. 2021 Feb;9(3):205
pubmed: 33708832
Mol Pharm. 2015 Sep 8;12(9):3282-91
pubmed: 26280109
Adv Exp Med Biol. 2000;486:257-61
pubmed: 11783495
J Pers Med. 2019 Feb 07;9(1):
pubmed: 30736475
BMC Cancer. 2015 Jul 25;15:550
pubmed: 26209226
Clin Cancer Res. 2016 Apr 1;22(7):1725-33
pubmed: 26561557
World J Gastroenterol. 2014 Jan 28;20(4):888-98
pubmed: 24574763
Clin Chim Acta. 2020 Oct;509:36-42
pubmed: 32502495
J Biol Chem. 1970 Jan 10;245(1):80-7
pubmed: 5411547
Annu Rev Biochem. 2016 Jun 2;85:375-404
pubmed: 27145840
Nature. 2014 Jun 12;510(7504):288-92
pubmed: 24870241
Mol Cell Biol. 1995 May;15(5):2612-24
pubmed: 7739542
Cancer Chemother Pharmacol. 1995;36(6):513-23
pubmed: 7554044
J Biol Chem. 2010 Feb 19;285(8):5274-81
pubmed: 20018861
J Biol Chem. 2010 Oct 29;285(44):33727-36
pubmed: 20739275
Sci Rep. 2017 Jul 11;7(1):5129
pubmed: 28698581
Nature. 1978 Jan 5;271(5640):71-3
pubmed: 203856
Science. 1992 Sep 25;257(5078):1958-61
pubmed: 1329201
Biomed Res Int. 2017;2017:1506824
pubmed: 29318140
J Cell Sci. 2020 Mar 6;133(5):
pubmed: 32144194
Cancer Res. 2022 Mar 15;82(6):1013-1024
pubmed: 35022212
Mol Cell Biochem. 1994 Nov 9;140(1):1-22
pubmed: 7877593
Biochim Biophys Acta. 2000 Jul 24;1492(2-3):548-52
pubmed: 10899599
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Drug Discov Today. 2020 Feb;25(2):406-413
pubmed: 31839441
J Exp Clin Cancer Res. 2019 Apr 8;38(1):152
pubmed: 30961661
EMBO J. 1998 Sep 1;17(17):5015-25
pubmed: 9724637